De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
作者信息
Papamichael Konstantinos, Karatzas Pantelis, Mantzaris Gerasimos J
机构信息
Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
Department of Gastroenterology, Evangelismos Hospital, Athens, Greece
出版信息
J Crohns Colitis. 2016 Mar;10(3):371-2. doi: 10.1093/ecco-jcc/jjv206. Epub 2015 Nov 6.
Abstract
摘要
相似文献
1
De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
J Crohns Colitis. 2016 Mar;10(3):371-2. doi: 10.1093/ecco-jcc/jjv206. Epub 2015 Nov 6.
2
Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312.
3
Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Aliment Pharmacol Ther. 2011 Aug;34(4):462-9. doi: 10.1111/j.1365-2036.2011.04743.x. Epub 2011 Jun 14.
4
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Inflamm Bowel Dis. 2017 Jan;23(1):126-132. doi: 10.1097/MIB.0000000000000986.
5
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Dig Dis. 2019;37(2):108-115. doi: 10.1159/000492626. Epub 2018 Aug 27.
6
Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
PLoS One. 2015 Dec 15;10(12):e0144900. doi: 10.1371/journal.pone.0144900. eCollection 2015.
7
Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Eur J Gastroenterol Hepatol. 2015 Apr;27(4):436-41. doi: 10.1097/MEG.0000000000000303.
8
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab.
Dig Liver Dis. 2024 May;56(5):737-743. doi: 10.1016/j.dld.2023.10.027. Epub 2023 Nov 18.
9
Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
Scand J Gastroenterol. 2016 Dec;51(12):1447-1452. doi: 10.1080/00365521.2016.1205128. Epub 2016 Jul 12.
10
Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2018 Jul;30(7):699-703. doi: 10.1097/MEG.0000000000001113.
引用本文的文献
1
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.
Therap Adv Gastroenterol. 2021 Dec 9;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021.
2
Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.
BMJ Open. 2021 Nov 3;11(11):e054154. doi: 10.1136/bmjopen-2021-054154.
3
Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
World J Gastroenterol. 2021 Sep 7;27(33):5520-5535. doi: 10.3748/wjg.v27.i33.5520.
4
[Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers].
Z Gastroenterol. 2020 Jul;58(7):672-692. doi: 10.1055/a-1193-5475. Epub 2020 Jul 13.
5
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
J Crohns Colitis. 2019 Aug 14;13(8):1012-1024. doi: 10.1093/ecco-jcc/jjz023.
6
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.
EBioMedicine. 2017 Jul;21:123-130. doi: 10.1016/j.ebiom.2017.06.004. Epub 2017 Jun 7.
本文引用的文献
1
Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2015 Oct;42(7):939-40. doi: 10.1111/apt.13335.
2
Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
Inflamm Bowel Dis. 2015 Jun;21(6):1359-67. doi: 10.1097/MIB.0000000000000376.
3
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.
4
Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
J Crohns Colitis. 2015 Jan;9(1):33-40. doi: 10.1016/j.crohns.2014.06.012.
5
Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
Aliment Pharmacol Ther. 2014 Aug;40(4):338-53. doi: 10.1111/apt.12838. Epub 2014 Jun 23.
Zotero 插件